Pancreatic Cancer Research

ResearcherOsaka City UniversityActive in the last 2 years

Hideki Wanibuchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9362-4290; OpenAlex author ID A5085745863. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17132212↗
  2. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000220↗
  3. MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways. Last author DOI 10.3892/ijo.2013.1760↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuko Kuwae · 2 shared papers, 2015–2025 · strength 0.27
  2. Anna Kakehashi · 2 shared papers, 2015–2025 · strength 0.27
  3. Norifumi Kawada · 1 shared paper, 2025 · strength 0.22
  4. Hirotaka Hoshi · 1 shared paper, 2013 · strength 0.04
  5. Kenjiro Kimura · 1 shared paper, 2013 · strength 0.04
  6. Kosei Hirakawa · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.